Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (NCT05030428)

🧪 Interventions in This Study

• Inclisiran sodium 300 mg (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (983 Sites)

Showing the first 25 of 983 sites.

• UAB St Vincents — Birmingham, Alabama
• Eastern Shore Research Institute — Fairhope, Alabama
• G and L Research LLC — Foley, Alabama
• Alaska Heart and Vascular — Anchorage, Alaska
• Mercy Gilbert Medical Center — Gilbert, Arizona
• Cardiovascular Associates of Mesa — Mesa, Arizona
• Elite Clinical Studies — Phoenix, Arizona
• HonorHealth Heart Group Deer Valley — Scottsdale, Arizona
• Clinical Research Inst of Arizona — Sun City West, Arizona
• Pima Heart And Vascular Clin Rch — Tucson, Arizona
• ARcare Center for Clinical Research — Little Rock, Arkansas
• Arkansas Clinical Research — Little Rock, Arkansas
• Central Cardiology Medical Center — Bakersfield, California
• Alliance Clinical — Canoga Park, California
• Inland Psychiatric Medical Group — Chino, California
• John Muir Physician Network Clinical Research Center — Concord, California
• Triallogix — Fullerton, California
• Diabetes Lipid Management Center — Huntington Beach, California
• University of Calif Irvine Med Cntr — Irvine, California
• UC San Diego Health — La Jolla, California
• American Institute of Research — Los Angeles, California
• Keck Medical Center USC — Los Angeles, California
• University of California LA — Los Angeles, California
• VA Palo Alto Health Care System — Palo Alto, California
• San Diego Veterans Medical Center — San Diego, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Atherosclerotic Cardiovascular Disease

• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Alexander City, Alabama
• A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease — Boston, Massachusetts
• VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease — Birmingham, Alabama
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Birmingham, Alabama
• Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE — Memphis, Tennessee

Explore by condition: All Atherosclerotic Cardiovascular Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.